These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 16841196)

  • 1. Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands.
    Gao W; Kim J; Dalton JT
    Pharm Res; 2006 Aug; 23(8):1641-58. PubMed ID: 16841196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective androgen receptor modulators: in pursuit of tissue-selective androgens.
    Omwancha J; Brown TR
    Curr Opin Investig Drugs; 2006 Oct; 7(10):873-81. PubMed ID: 17086931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs).
    Gao W; Dalton JT
    Drug Discov Today; 2007 Mar; 12(5-6):241-8. PubMed ID: 17331889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways.
    Narayanan R; Coss CC; Yepuru M; Kearbey JD; Miller DD; Dalton JT
    Mol Endocrinol; 2008 Nov; 22(11):2448-65. PubMed ID: 18801930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery.
    Segal S; Narayanan R; Dalton JT
    Expert Opin Investig Drugs; 2006 Apr; 15(4):377-87. PubMed ID: 16548787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications.
    Solomon ZJ; Mirabal JR; Mazur DJ; Kohn TP; Lipshultz LI; Pastuszak AW
    Sex Med Rev; 2019 Jan; 7(1):84-94. PubMed ID: 30503797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent developments in antiandrogens and selective androgen receptor modulators.
    Haendler B; Cleve A
    Mol Cell Endocrinol; 2012 Apr; 352(1-2):79-91. PubMed ID: 21704118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor antagonists (antiandrogens): structure-activity relationships.
    Singh SM; Gauthier S; Labrie F
    Curr Med Chem; 2000 Feb; 7(2):211-47. PubMed ID: 10637363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiandrogens in prostate cancer endocrine therapy.
    Culig Z; Bartsch G; Hobisch A
    Curr Cancer Drug Targets; 2004 Aug; 4(5):455-61. PubMed ID: 15320720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiandrogens in prostate cancer.
    Reid P; Kantoff P; Oh W
    Invest New Drugs; 1999; 17(3):271-84. PubMed ID: 10665479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ockham's razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5alpha-reductase?
    Gao W; Dalton JT
    Mol Interv; 2007 Feb; 7(1):10-3. PubMed ID: 17339601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the development of selective androgen receptor modulators.
    Zhang X; Lanter JC; Sui Z
    Expert Opin Ther Pat; 2009 Sep; 19(9):1239-58. PubMed ID: 19505196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A selective androgen receptor modulator with minimal prostate hypertrophic activity restores lean body mass in aged orchidectomized male rats.
    Allan G; Sbriscia T; Linton O; Lai MT; Haynes-Johnson D; Bhattacharjee S; Ng R; Sui Z; Lundeen S
    J Steroid Biochem Mol Biol; 2008 Jun; 110(3-5):207-13. PubMed ID: 18502117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective androgen receptor modulators in drug discovery: medicinal chemistry and therapeutic potential.
    Cadilla R; Turnbull P
    Curr Top Med Chem; 2006; 6(3):245-70. PubMed ID: 16515480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor modulators: a review of recent patents and reports (2012-2018).
    Fujii S; Kagechika H
    Expert Opin Ther Pat; 2019 Jun; 29(6):439-453. PubMed ID: 31092069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer.
    Dalton JT; Taylor RP; Mohler ML; Steiner MS
    Curr Opin Support Palliat Care; 2013 Dec; 7(4):345-51. PubMed ID: 24189892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgens and Selective Androgen Receptor Modulators to Treat Functional Limitations Associated With Aging and Chronic Disease.
    Bhasin S; Krishnan V; Storer TW; Steiner M; Dobs AS
    J Gerontol A Biol Sci Med Sci; 2023 Jun; 78(Suppl 1):25-31. PubMed ID: 37325955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate.
    Miner JN; Chang W; Chapman MS; Finn PD; Hong MH; López FJ; Marschke KB; Rosen J; Schrader W; Turner R; van Oeveren A; Viveros H; Zhi L; Negro-Vilar A
    Endocrinology; 2007 Jan; 148(1):363-73. PubMed ID: 17023534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor.
    Bohl CE; Miller DD; Chen J; Bell CE; Dalton JT
    J Biol Chem; 2005 Nov; 280(45):37747-54. PubMed ID: 16129672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.